New research demonstrates the ability of ADDomer ™ to tackle viral infections

New research has demonstrated the potential for the ADDomer ™ platform to produce thermostable vaccines and reagents to tackle viral infections The study led by the University of Bristol and Imophoron, a biopharmaceutical company developing thermostable nanoparticle vaccines using its ADDomer platform, is published in Antibody Therapeutics today [29 November].
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, International, Research; Institutes, Institutes, Bristol BioDesign Institute; Press Release Source Type: news